Efficacious Combination Drug Treatment for Colorectal Cancer that Overcomes Resistance to KRAS G12C Inhibitors

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global

cancer statistics 2020: GLOBOCAN estimates of incidence and mortality

worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–49.

2. Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a

review. JAMA 2021;325:669–85.

3. Moore AR, Rosenberg SC, McCormick F, Malek S. RAS-targeted therapies: is the

undruggable drugged? Nat Rev Drug Discov 2020;19:533–52.

4. Bos JL, Rehmann H, Wittinghofer A. GEFs and GAPs: critical elements in the

control of small G proteins. Cell 2007;129:865–77.

5. Kessler D, Gmachl M, Mantoulidis A, Martin LJ, Zoephel A, Mayer M, et al.

Drugging an undruggable pocket on KRAS. Proc Natl Acad Sci U S A 2019;116:

15823–9.

6. Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, et al. The clinical KRAS

(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 2019;575:

217–23.

7. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable

RAS: mission possible? Nat Rev Drug Discov 2014;13:828–51.

8. Kim D, Xue JY, Lito P. Targeting KRAS(G12C): from inhibitory mechanism to

modulation of antitumor effects in patients. Cell 2020;183:850–9.

9. Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, et al.

KRASG12C inhibition with Sotorasib in advanced solid tumors. N Eng J Med

2020;383:1207–17.

10. J€anne PA, Rybkin II, Spira AI, Riely GJ, Papadopoulos KP, Sabari JK, et al.

KRYSTAL-1: activity and safety of adagrasib (MRTX849) in advanced/metastatic non-small-cell lung cancer (NSCLC) harboring KRAS G12C mutation.

Eur J Cancer 2020;138(suppl 2):S1–S2.

11. Fakih MG, Kopetz S, Kuboki Y, Kim TW, Munster PN, Krauss JC, et al. Sotorasib

for previously treated colorectal cancers with KRAS(G12C) mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol

2022;23:115–24.

12. Xue JY, Zhao Y, Aronowitz J, Mai TT, Vides A, Qeriqi B, et al. Rapid nonuniform adaptation to conformation-specific KRAS(G12C) inhibition. Nature

2020;577:421–5.

13. Ryan MB, de la Cruz FF, Phat S, Myers DT, Wong E, Shahzade HA, et al. Vertical

pathway inhibition overcomes adaptive feedback resistance to KRAS(G12C)

inhibition. Clin Cancer Res 2020;26:1633–43.

AACRJournals.org

14. Amodio V, Yaeger R, Arcella P, Cancelliere C, Lamba S, Lorenzato A, et al. EGFR

blockade reverts resistance to KRAS G12C inhibition in colorectal cancer.

Cancer Discov 2020;10:1129–39.

15. Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernandez-Mateos J, Khan K,

et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 2018;359:920–6.

16. Miyoshi H, Maekawa H, Kakizaki F, Yamaura T, Kawada K, Sakai Y, et al. An

improved method for culturing patient-derived colorectal cancer spheroids.

Oncotarget 2018;9:21950–64.

17. Ishiguro T, Ohata H, Sato A, Yamawaki K, Enomoto T, Okamoto K. Tumorderived spheroids: relevance to cancer stem cells and clinical applications.

Cancer Sci 2017;108:283–9.

18. Maekawa H, Miyoshi H, Yamaura T, Itatani Y, Kawada K, Sakai Y, et al. A

chemosensitivity study of colorectal cancer using xenografts of patient-derived

tumor-initiating cells. Mol Cancer Ther 2018;17:2187–96.

19. Yamamoto T, Miyoshi H, Kakizaki F, Maekawa H, Yamaura T, Morimoto T,

et al. Chemosensitivity of patient-derived cancer stem cells identifies colorectal

cancer patients with potential benefit from FGFR inhibitor therapy. Cancers

2020;12:2010.

20. Young A, Lou D, McCormick F. Oncogenic and wild-type Ras play divergent

roles in the regulation of mitogen-activated protein kinase signaling.

Cancer Discov 2013;3:112–23.

21. VanDussen KL, Marinshaw JM, Shaikh N, Miyoshi H, Moon C, Tarr PI, et al.

Development of an enhanced human gastrointestinal epithelial culture system to

facilitate patient-based assays. Gut 2015;64:911–20.

22. Miyoshi H, VanDussen KL, Malvin NP, Ryu SH, Wang Y, Sonnek NM, et al.

Prostaglandin E2 promotes intestinal repair through an adaptive cellular

response of the epithelium. EMBO J 2017;36:5–24.

23. Janes MR, Zhang J, Li LS, Hansen R, Peters U, Guo X, et al. Targeting

KRAS mutant cancers with a covalent G12C-specific inhibitor. Cell 2018;

172:578–89.

24. Fell JB, Fischer JP, Baer BR, Blake JF, Bouhana K, Briere DM, et al. Identification

of the clinical development candidate MRTX849, a covalent KRAS(G12C)

inhibitor for the treatment of cancer. J Med Chem 2020;63:6679–93.

25. Nichols RJ, Haderk F, Stahlhut C, Schulze CJ, Hemmati G, Wildes D, et al.

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of

Mol Cancer Ther; 22(4) April 2023

537

Matsubara et al.

26.

27.

28.

29.

30.

mutant BRAF-, NF1- and RAS-driven cancers. Nat Cell Biol 2018;20:

1064–73.

Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of

genetic variants from high-throughput sequencing data. Nucleic Acids Res

2010;38:e164.

Higasa K, Miyake N, Yoshimura J, Okamura K, Niihori T, Saitsu H, et al. Human

genetic variation database, a reference database of genetic variations in the

Japanese population. J Hum Genet 2016;61:547–53.

Nagasaki M, Yasuda J, Katsuoka F, Nariai N, Kojima K, Kawai Y, et al. Rare

variant discovery by deep whole-genome sequencing of 1,070 Japanese individuals. Nat Commun 2015;6:8018.

Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, et al. The

KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov

2020;10:54–71.

Misale S, Fatherree JP, Cortez E, Li C, Bilton S, Timonina D, et al. KRAS G12C

NSCLC models are sensitive to direct targeting of KRAS in combination with

PI3K inhibition. Clin Cancer Res 2019;25:796–807.

31. Martini M, De Santis MC, Braccini L, Gulluni F, Hirsch E. PI3K/AKT signaling

pathway and cancer: an updated review. Ann Med 2014;46:372–83.

32. Danielsen SA, Eide PW, Nesbakken A, Guren T, Leithe E, Lothe RA. Portrait of

the PI3K/AKT pathway in colorectal cancer. Biochim Biophys Acta 2015;1855:

104–21.

33. Mujoo K, Choi BK, Huang Z, Zhang N, An Z. Regulation of ERBB3/HER3

signaling in cancer. Oncotarget 2014;5:10222–36.

34. Chen YNP, LaMarche MJ, Chan HM, Fekkes P, Garcia-Fortanet J, Acker MG,

et al. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by

receptor tyrosine kinases. Nature 2016;535:148–52.

35. Adachi Y, Ito K, Hayashi Y, Kimura R, Tan TZ, Yamaguchi R, et al. Epithelial-tomesenchymal transition is a cause of both intrinsic and acquired resistance to

KRAS G12C inhibitor in KRAS G12C-mutant non-small cell lung cancer.

Clin Cancer Res 2020;26:5962–73.

36. De Boeck A, Pauwels P, Hensen K, Rummens JL, Westbroek W, Hendrix A, et al.

Bone marrow-derived mesenchymal stem cells promote colorectal cancer

progression through paracrine neuregulin 1/HER3 signalling. Gut 2013;62:

550–60.

Downloaded from http://aacrjournals.org/mct/article-pdf/22/4/529/3318320/529.pdf by Kyoto University user on 04 April 2023

538 Mol Cancer Ther; 22(4) April 2023

MOLECULAR CANCER THERAPEUTICS

...